TY - JOUR
T1 - Exploring new prognostic biomarkers in Mantle Cell Lymphoma
T2 - a comparison of the circSCORE and the MCL35 score
AU - Salim, Ruth
AU - Husby, Simon
AU - Winther Eskelund, Christian
AU - Scott, David W
AU - Holte, Harald
AU - Kolstad, Arne
AU - Räty, Riikka
AU - Ek, Sara
AU - Jerkeman, Mats
AU - Geisler, Christian
AU - Sommer Kristensen, Lasse
AU - Dahl, Mette
AU - Grønbæk, Kirsten
PY - 2023
Y1 - 2023
N2 - Mantle cell lymphoma (MCL) is a biologically and clinically heterogeneous disease, emphasizing the need for prognostic biomarkers. In this study we aimed at comparing the prognostic value of two RNA-based risk scores, circSCORE and MCL35, in 149 patients from the MCL2 (ISRCTN87866680) and MCL3 (NCT00514475) patient cohorts. Both risk scores provided significant stratification of high versus low risk for progression free survival (PFS) and overall survival (OS). The circSCORE retained significant prognostic value in adjusted multivariable Cox regressions for PFS, but not for OS. Furthermore, circSCORE added significant prognostic value to MIPI in the pooled cohort (MCL2 and MCL3) for PFS and OS, and for PFS in MCL3 alone, outperforming Ki67 and MCL35. We suggest a new, combined MIPI-circSCORE with improved prognostic value, and with potential for future clinical implementation, if validated in a larger, independent cohort.
AB - Mantle cell lymphoma (MCL) is a biologically and clinically heterogeneous disease, emphasizing the need for prognostic biomarkers. In this study we aimed at comparing the prognostic value of two RNA-based risk scores, circSCORE and MCL35, in 149 patients from the MCL2 (ISRCTN87866680) and MCL3 (NCT00514475) patient cohorts. Both risk scores provided significant stratification of high versus low risk for progression free survival (PFS) and overall survival (OS). The circSCORE retained significant prognostic value in adjusted multivariable Cox regressions for PFS, but not for OS. Furthermore, circSCORE added significant prognostic value to MIPI in the pooled cohort (MCL2 and MCL3) for PFS and OS, and for PFS in MCL3 alone, outperforming Ki67 and MCL35. We suggest a new, combined MIPI-circSCORE with improved prognostic value, and with potential for future clinical implementation, if validated in a larger, independent cohort.
KW - MCL35
KW - Mantle cell lymphoma
KW - circRNA
KW - circSCORE
KW - mRNA
KW - prognostic biomarkers
UR - http://www.scopus.com/inward/record.url?scp=85161371345&partnerID=8YFLogxK
U2 - 10.1080/10428194.2023.2216819
DO - 10.1080/10428194.2023.2216819
M3 - Journal article
C2 - 37259807
SN - 1042-8194
VL - 64
SP - 1414
EP - 1423
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 8
ER -